{"article":{"annotation":{"article_id":"brazil-anvisa-bans-irregular-medicines-october-2026","available_at":"2026-10-12T09:41:13.312594Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"fcc5d3df1bb9d906b2afbf184cd3c33491d692bed7dffd99fc4f9e11489644e7","input_sha256":"84c77bb6fc89b5b4b5d6e3988ba3f7db1fcbcdb62002596a16975f03c11a4e89","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"BR","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"geometry":null,"id":"iso3166-1:BR","kind":"country-or-area","labels":{"ar":"البرازيل","en":"Brazil","es":"Brasil","fr":"Brésil"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=fr","category":"health","content":{"key_points":[],"paragraphs":["L’autorité sanitaire brésilienne Anvisa a interdit la vente de plusieurs médicaments irréguliers le 6 octobre. Les mesures concernent une insuline glargine distribuée par une entreprise sans autorisation, un médicament composé commercialisé auprès du public sans ordonnance et des peptides non enregistrés.","Anvisa a également signalé le rappel volontaire par le fabricant d’un lot d’Imaavy et ordonné le rappel d’un lot de l’antibiotique Lizbi après avoir confirmé une perte de stérilité liée à un emballage endommagé. Cet article rend compte des mesures réglementaires et ne constitue pas un conseil médical individuel."],"sections":[]},"corrections":[{"at":"2026-10-07T00:55:00+03:00","language":"fr","text":"Des éditions allemande et portugaise, ainsi que les traductions des explications des données et des corrections, ont été ajoutées à cet article."},{"at":"2026-10-12T06:25:46+03:00","language":"fr","text":"Les traductions intégrales des cellules textuelles des tableaux ont été ajoutées dans les sept langues. Les valeurs originales des sources et les observations numériques ont été conservées."},{"at":"2026-10-12T06:25:47+03:00","language":"fr","text":"La formulation des éditions linguistiques de cet article a été corrigée afin de conserver toutes ses informations et leur portée."}],"country":"BR","data":{"blocks":[{"columns":[{"key":"item","label":{"ar":"المنتج أو الفئة","de":"Produkt oder Kategorie","en":"Product or category","es":"Producto o categoría","fr":"Produit ou catégorie","pt":"Produto ou categoria","tr":"Ürün veya kategori"},"language":"en","type":"text"},{"key":"action","label":{"ar":"إجراء أنفيسا","de":"Maßnahme von Anvisa","en":"Anvisa action","es":"Medida de Anvisa","fr":"Mesure de l’Anvisa","pt":"Medida da Anvisa","tr":"Anvisa işlemi"},"language":"en","type":"text"}],"description":{"ar":"فئات المنتجات وأنواع الإجراءات في إعلان أنفيسا بتاريخ 6 أكتوبر 2026.","de":"Produkte und Maßnahmen in der Mitteilung von Anvisa vom 6. Oktober 2026.","en":"Products and action types in Anvisa’s October 6, 2026 notice.","es":"Productos y tipos de medidas del aviso de Anvisa del 6 de octubre de 2026.","fr":"Produits et types de mesures dans l’avis de l’Anvisa du 6 octobre 2026.","pt":"Produtos e tipos de medida no comunicado da Anvisa de 6 de outubro de 2026.","tr":"Anvisa’nın 6 Ekim 2026 duyurusundaki ürün grupları ve karar türleri."},"id":"brazil-anvisa-regulatory-actions","methodology":{"ar":"يلخص الجدول نطاق الإعلان وفق نص المصدر؛ ولا يقدم إرشاداً طبياً.","de":"Die Tabelle fasst den Umfang der Mitteilung mit den Begriffen der Quelle zusammen und enthält keine medizinische Beratung.","en":"The table summarizes the scope of the notice in the source’s terms; it does not provide medical guidance.","es":"La tabla resume el alcance del aviso según el texto fuente; no ofrece orientación médica.","fr":"Le tableau résume le champ de l’avis selon le texte source ; il ne fournit pas de conseil médical.","pt":"A tabela resume o escopo do comunicado nos termos da fonte; não fornece orientação médica.","tr":"Tablo karar kapsamını kaynak metindeki ifadelerle özetler; listelenen ilaçlar için tıbbi öneri içermez."},"rowTranslations":[{"action":{"ar":"حُظر بيع جميع الدفعات؛ ولم تكن جهة التوزيع مرخصة.","de":"Der Verkauf aller Chargen ist verboten; der Vertrieb hatte keine Genehmigung.","en":"Sale of all lots prohibited; distributor lacked authorization.","es":"Prohibida la venta de todos los lotes; el distribuidor carecía de autorización.","fr":"Vente de tous les lots interdite ; le distributeur n’était pas autorisé.","pt":"A venda de todos os lotes foi proibida; o distribuidor não tinha autorização.","tr":"Tüm lotların satışı yasaklandı; dağıtım şirketinin yetkisi yoktu."},"item":{"ar":"إنسولين غلارجين 3 mL/100 IU، Costa Mar","de":"Insulin glargin 3 mL/100 IU, Costa Mar","en":"Insulin glargine 3 mL/100 IU, Costa Mar","es":"Insulina glargina 3 mL/100 IU, Costa Mar","fr":"Insuline glargine 3 mL/100 IU, Costa Mar","pt":"Insulina glargina 3 mL/100 IU, Costa Mar","tr":"İnsülin glarjin 3 mL/100 IU, Costa Mar"}},{"action":{"ar":"حُظر البيع والتوزيع والإعلان؛ واستندت الهيئة إلى تسويق دواء مركّب موحّد وغير مخصص لفرد بعينه دون وصفة طبية.","de":"Verkauf, Vertrieb und Werbung verboten; die Behörde verwies auf die Vermarktung eines standardisierten, nicht patientenindividuell hergestellten Rezepturarzneimittels ohne Verschreibung.","en":"Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription.","es":"Prohibidas la venta, distribución y publicidad; el regulador señaló la comercialización sin receta de un medicamento compuesto estandarizado y no individualizado.","fr":"Vente, distribution et publicité interdites ; l’autorité a invoqué la commercialisation sans ordonnance d’un médicament composé standardisé et non individualisé.","pt":"Venda, distribuição e publicidade proibidas; o órgão regulador citou a comercialização sem receita de medicamento manipulado padronizado e não individualizado.","tr":"Satış, dağıtım ve tanıtım yasaklandı; düzenleyici kurum, kişiye özel hazırlanmayan standart bir bileşik ilacın reçete olmadan pazarlanmasını gerekçe gösterdi."},"item":{"ar":"دواء Vermefree مُركّب، Sintonia Pharma","de":"Rezepturarzneimittel Vermefree, Sintonia Pharma","en":"Vermefree compounded medicine, Sintonia Pharma","es":"Medicamento compuesto Vermefree, Sintonia Pharma","fr":"Médicament composé Vermefree, Sintonia Pharma","pt":"Medicamento manipulado Vermefree, Sintonia Pharma","tr":"Vermefree bileşik ilaç, Sintonia Pharma"}},{"action":{"ar":"حُظر البيع والتصنيع والتوزيع والإعلان والنقل والاستخدام.","de":"Verkauf, Herstellung, Vertrieb, Werbung, Transport und Verwendung sind verboten.","en":"Sale, manufacture, distribution, advertising, transport and use prohibited.","es":"Prohibidos la venta, fabricación, distribución, publicidad, transporte y uso.","fr":"Vente, fabrication, distribution, publicité, transport et utilisation interdits.","pt":"Venda, fabricação, distribuição, publicidade, transporte e uso proibidos.","tr":"Satış, üretim, dağıtım, tanıtım, taşıma ve kullanım yasaklandı."},"item":{"ar":"ببتيدات غير مسجلة واردة في البيان","de":"In der Mitteilung aufgeführte nicht registrierte Peptide","en":"Unregistered peptides listed in notice","es":"Péptidos sin registro incluidos en el aviso","fr":"Peptides non enregistrés mentionnés dans l’avis","pt":"Peptídeos não registrados listados no comunicado","tr":"Duyuruda listelenen kayıtsız peptitler"}},{"action":{"ar":"أُبلغ عن سحب طوعي؛ مع احتمال وجود جزيئات زجاجية في القوارير.","de":"Freiwilliger Rückruf gemeldet; möglicherweise befinden sich Glaspartikel in den Durchstechflaschen.","en":"Voluntary recall reported; possible glass particles in vials.","es":"Retirada voluntaria comunicada; posible presencia de partículas de vidrio en los viales.","fr":"Rappel volontaire signalé ; présence possible de particules de verre dans les flacons.","pt":"Recolhimento voluntário informado; há possibilidade de partículas de vidro nos frascos.","tr":"Gönüllü geri çağırma bildirildi; flakonlarda cam parçacıkları bulunma olasılığı var."},"item":{"ar":"دفعة Imaavy رقم JNYJ1201","de":"Charge Imaavy JNYJ1201","en":"Imaavy batch JNYJ1201","es":"Lote de Imaavy JNYJ1201","fr":"Lot Imaavy JNYJ1201","pt":"Lote de Imaavy JNYJ1201","tr":"Imaavy lotu JNYJ1201"}},{"action":{"ar":"أُمر بسحبها بعد تأكيد فقدان التعقيم المرتبط بتضرر سلامة العبوة الأولية.","de":"Rückruf angeordnet, nachdem ein mit der beeinträchtigten Unversehrtheit der Primärverpackung verbundener Verlust der Sterilität bestätigt wurde.","en":"Recall ordered after confirmed sterility loss linked to compromised primary packaging.","es":"Retirada ordenada tras confirmarse la pérdida de esterilidad vinculada al deterioro de la integridad del envase primario.","fr":"Rappel ordonné après confirmation d’une perte de stérilité liée à une atteinte à l’intégrité de l’emballage primaire.","pt":"Recolhimento determinado após a confirmação de perda de esterilidade associada ao comprometimento da integridade da embalagem primária.","tr":"Birincil ambalaj bütünlüğünün bozulmasıyla bağlantılı sterilite kaybının doğrulanmasının ardından geri çağırma emri verildi."},"item":{"ar":"دفعة Lizbi رقم 0000207107","de":"Charge Lizbi 0000207107","en":"Lizbi batch 0000207107","es":"Lote de Lizbi 0000207107","fr":"Lot Lizbi 0000207107","pt":"Lote de Lizbi 0000207107","tr":"Lizbi lotu 0000207107"}}],"rows":[{"action":"Sale of all lots prohibited; distributor lacked authorization.","item":"Insulin glargine 3 mL/100 IU, Costa Mar"},{"action":"Sale, distribution and advertising prohibited; regulator cited standardized non-individualized compounding marketed without prescription.","item":"Vermefree compounded medicine, Sintonia Pharma"},{"action":"Sale, manufacture, distribution, advertising, transport and use prohibited.","item":"Unregistered peptides listed in notice"},{"action":"Voluntary recall reported; possible glass particles in vials.","item":"Imaavy batch JNYJ1201"},{"action":"Recall ordered after confirmed sterility loss linked to compromised primary packaging.","item":"Lizbi batch 0000207107"}],"sourceUrls":["https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"],"title":{"ar":"الأدوية المحظورة أو المسحوبة","de":"Verbotene oder zurückgerufene Arzneimittel","en":"Medicines prohibited or recalled","es":"Medicamentos prohibidos o retirados","fr":"Médicaments interdits ou rappelés","pt":"Medicamentos proibidos ou recolhidos","tr":"Yasaklanan veya geri çağrılan ilaçlar"},"type":"table","updatedAt":"2026-10-12T06:25:46+03:00"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=fr&format=csv","json":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026/data/brazil-anvisa-regulatory-actions?lang=fr&format=json"},"id":"brazil-anvisa-regulatory-actions"}],"data_types":["table"],"editorial_illustration":{"alt":"Illustration conceptuelle de la santé publique, de la recherche et des données connectées.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"fr","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-8ff1924c-3faa-55d0-982f-f85ffe24522b","event_period":"2026-10-06","event_period_basis":"event-or-reference-period","id":"brazil-anvisa-bans-irregular-medicines-october-2026","image":null,"importance":0.6,"language":"fr","modified_at":"2026-10-12T06:25:47+03:00","publication_basis":"publication-record","published_at":"2026-10-06T17:11:49+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Illustration conceptuelle de la santé publique, de la recherche et des données connectées.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"fr","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"brazil-anvisa-bans-irregular-medicines-october-2026","sources":[{"checkedAt":"2026-10-06","name":"National Health Surveillance Agency of Brazil","publishedAt":"2026-10-06","url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/anvisa-proibe-venda-de-insulina-e-tirzepatida-irregulares-1"}],"summary":"Les interdictions portent sur une insuline distribuée sans autorisation, un médicament composé irrégulièrement et des peptides non enregistrés, ainsi que deux lots présentant des problèmes de qualité.","text":"Les interdictions portent sur une insuline distribuée sans autorisation, un médicament composé irrégulièrement et des peptides non enregistrés, ainsi que deux lots présentant des problèmes de qualité.\n\nL’autorité sanitaire brésilienne Anvisa a interdit la vente de plusieurs médicaments irréguliers le 6 octobre. Les mesures concernent une insuline glargine distribuée par une entreprise sans autorisation, un médicament composé commercialisé auprès du public sans ordonnance et des peptides non enregistrés.\n\nAnvisa a également signalé le rappel volontaire par le fabricant d’un lot d’Imaavy et ordonné le rappel d’un lot de l’antibiotique Lizbi après avoir confirmé une perte de stérilité liée à un emballage endommagé. Cet article rend compte des mesures réglementaires et ne constitue pas un conseil médical individuel.\n\nDes éditions allemande et portugaise, ainsi que les traductions des explications des données et des corrections, ont été ajoutées à cet article.\n\nLes traductions intégrales des cellules textuelles des tableaux ont été ajoutées dans les sept langues. Les valeurs originales des sources et les observations numériques ont été conservées.\n\nLa formulation des éditions linguistiques de cet article a été corrigée afin de conserver toutes ses informations et leur portée.","title":"L’Anvisa interdit la vente de médicaments irréguliers au Brésil","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/brazil-anvisa-bans-irregular-medicines-october-2026"},{"api_url":"https://newsverum.com/api/v1/articles/brazil-anvisa-bans-irregular-medicines-october-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/brazil-anvisa-bans-irregular-medicines-october-2026"}],"url":"https://newsverum.com/fr/news/brazil-anvisa-bans-irregular-medicines-october-2026"},"version":"1"}
